AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

A pup named Valentina was returned to a shelter just before the holidays, and her heartbroken face has gone viral on social media. "Valentina was returned. She doesn't understand why," reads the ...

American drug major AbbVie Healthcare’s Indian arm, which is under the scanner for sponsoring foreign trips of 30 doctors in violation of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP ...

The Apex Committee for Pharma Marketing Practices has found Abbvie Healthcare India Private Ltd in breach of the UCPMP ( Uniform Code for Pharmaceutical Marketing Practices), by sponsoring ...

The department of pharmaceuticals (DoP) reprimanded AbbVie Healthcare India for unethical marketing practices involving over ₹1 crore spent on foreign vacations for 30 doctors under the guise of ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other best stocks to buy and hold for 3 years. On December 12, Tom Lee, Fundstrat Global Advisors ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...

Polaris Global Equity Strategy highlighted stocks like AbbVie Inc. (NYSE:ABBV) in its Q3 2024 investor letter. AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals.

The retail sector is expanding with innovations in social commerce, AI, personalization, and automation, driving improved outcomes. Consumer spending has increased on goods like apparel and essentials ...

(Each year, TIME recognizes 100 companies that are revolutionizing the world. Apply now to have your company reviewed by our editors.) At the end of 2012, T-Mobile US was not in a good place.

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on ...